Sarepta stock surges more than 10% as results top expectations, drug given priority review

Sarepta Therapeutics Inc. SRPT shares rallied in the extended session Tuesday after the biotech drug maker topped Wall Street expectations, and said U.S. regulators granted a priority review status fo...

SRPT Stock Surges On Potential Accelerated Approval For Gene Therapy

The Food and Drug Administration said Monday it will perform a speedy review of Sarepta Therapeutics‘ (SRPT) muscular dystrophy gene therapy, and SRPT stock jumped. X Sarepta filed for approval ...